Small Cap Gainers: ZIOP, ADAP, OPAD
3:31 pm Tuesday, September 07th, 2021
ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) spikes to its highest levels since July on heavy volume. Among recent items, several of co’s directors on Friday evening disclosed recent purchase transactions for close to 250K of co’s shares valued collectively at approx. ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer.
Adaptimmune Therapeutics PLC (NASDAQ: ADAP) soared 30% after the company announced a strategic collaboration and license agreement with Roche’s (RHHBY) Genentech to develop and commercialize allogeneic cell therapies for multiple oncology indications; per the agreement, co will receive an upfront payment of $150 mln and additional payments of $150 mln over five years and will be eligible for milestone payments potentially exceeding $3 bln, in addition to royalties. Also provided updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer. Rises to its highest levels since February.
Offerpad Solutions Inc (NYSE: OPAD) spikes on heavy volume; co completed its combination with SPAC Supernova Partners Acquisition Company late last week. Offerpad Solutions Inc. engages in buying, selling, renting, and renovating properties to homeowners in the United States. It operates iBuying, a real estate solutions platform, which includes that empowers homeowners with customizable solutions and home selling experience. The company was founded in 2015 and is based in Gilbert, Arizona.
